Don't think any dropped out......this was the same announcement last year.
Brisbane, Australia, 16 November 2016 -- ResApp Health Limited (ASX: RAP), the
developer of smartphone medical applications for the diagnosis and management of
respiratory disease, today announced that it has received institutional review board
approval at Baylor College of Medicine and Texas Children’s Hospital for the
SMARTCOUGH-C study.
RAP Price at posting:
7.2¢ Sentiment: Buy Disclosure: Held